About this episode

The episode discusses Poolbeg Pharma's first patient dosed in the POLB 001 clinical trial and its implications for investors.

Watch on YouTube Poolbeg Pharma has dosed the first patient in its POLB 001 TOPICAL clinical trial, marking the start of a key execution phase for its CRS prevention programme. With UCLH activated, further sites expected, interim data targeted for summer 2026 and partnering discussions ongoing, investors will be watching whether clinical progress can validate the programme’s claimed commercial potential.

Topics covered

• biotech
• clinical trials
• investing
• pharmaceuticals
• CRS prevention
• healthcare

Keywords

• Poolbeg Pharma
• POLB 001
• clinical trial
• CRS prevention
• biotech investment
• UCLH
• interim data

Mentioned in this episode

Organizations: Poolbeg Pharma, UCLH

Products: POLB 001

More episodes of The Vox Markets Podcast

• 2448: The Exchange with Richard Crow · July 20, 2026 · 1h 49m
• 2447: 2 P's on a Pod: Could More UK Takeovers Follow? · July 17, 2026 · 1h 19m
• 2446: Winshear Metals: Massive sulphides at Portsoy? · July 16, 2026 · 8 min
• 2444: European Green Transition: Potential £126m Repowering Revenue Opportunity · July 13, 2026 · 7 min
• 2443: 2 P's on a Pod: What Happens Next for UK Small Caps? · July 10, 2026 · 1h 20m
• 2442: Q&A with Verici DX CEO Sara Barrington · July 10, 2026 · 21 min

Explore listener stats, chart rankings, contacts and more on the The Vox Markets Podcast podcast page.